Translate page

 

 We are very grateful for the support of Brandcast media to produce this web stream
VEP Soverini

 

 

  

        

 

 

Mutation Screening:
What is standard of care today and the role of new modalities
Simona Soverini, University of Bologna, Italy 

  • BCR-ABL kinase domain (KD) mutation for optimal patient management
  • When to perform BCR-ABL KD mutation analysis
  • How to perform BCR-ABL KD mutation analysis
  • BCR-ABL KD mutation screening: key issues
  • Next-generation sequencing (NGS): applications
  • NGS for routine BCR-ABL mutatation testing: when?
  • NGS for routine BCR-ABL mutation screening: hurdles
  • Conclusions

Timothy Hughes.png

Prof. Tim Hughes

 

 Session 1: Frontline CML

  • Current clinical issues 
    (Prof. Tim Hughes)

 

 

 
VEP Mahon 

 

 

  

        

Stopping TKI therapy in Chronic Myeloid Leukemia
Francois-Xavier Mahon, Hospital University of Bordeaux, France 

  • What are the criteria for stopping treatment?
  • What is the definition of molecular relapse triggering re-treatment?
  • Is it safe to stop treatment?
  • Can we cure CML?

VEP Suttorp                

Treating pediatric Chronic Myeloid Leukemia - an update
Meinolf Suttorp, University Hospital Dresden, Germany 

  • Age specific incidence of CML
  • Value of adult scores in pediatric patients
  • Guidelines for the management of CML in children 
  • Compliance issues with pediatric patients
  • Side effects of TKI treatment in pediatric cohorts

We are pleased to make available a new series of presentations on various aspects of CML management that were first presented at the 22nd Meeting of the European Hematology Association (EHA) in Madrid in 2017. Modules currently featured include; how to treat CML in 2017, factors affecting clinical decision making in relapsed and refractory CP-CML patients and treatment outcomes of bosutinib from real-world data. 

 We are very grateful for the support of Brandcast media to produce these webstreams.
EHA Andreas Hochhaus

 

 

  

        

 

How to treat CML in 2017?
Andreas Hochhaus, Universitätsklinikum Jena, Germany 

  • Objectives of treatment optimization
  • Choice of initial therapy
  • Clinical data on 1st and 2nd generation TKI's
  • Comorbidities in CML at diagnosis
  • Main adverse events of TKI's
  • ELN recommendations for monitoring of first-line TKI therapy
  • Recommendations for switch: CP-CML
  • Management of blast crisis
  • Limitations of TKI therapies
  • Discussion: are we ready for routine stopping procedure?
  • Recommendations on CML management 2013 - 2017

This presentation is adapted from the one presented during the CML educational session at EHA. It lasts around 30 minutes.

 

EHA Delphine Rea

 

 

  

        

 

Factors affecting clinical decision making in refractory and relapsed CP-CML patients
Delphine Réa, Centre Hospitalo-Universitaire Saint-Louis, Paris, France

  • TKI resistance: significance and definition 
  • BCR-ABL1 mutations and resistance to imatinib and 2nd generation TKI's
  • Failure of 1st and 2nd generation TKI's
  • Mortality and causes of death in CP-CML patients during 2nd or subsequent line TKI
  • Responses to 3rd line therapy after resistance or intolerance to 2nd generation TKI
  • 5-year results from the PACE study: Responses to ponatinib in CP-CML patients
  • Therapeutic innovation: allosteric inhibition of BCR-ABL1 by ABL001
  • Conclusion and perspective

This presentation is adapted from one given during the industry sponsored symposium at EHA.